Similarly, in the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial performed in 874 patients with decompensated HF, circulating KIM-1 at baseline and during hospitalization was not associated with adverse clinical outcomes [11]. This evidence concerns the gene HAVCR1 and hydrops fetalis.